Jeroen Bakker, PhD, joined the previous biopharma fund in 2015 as an Analyst and transitioned to Associate in March 2016. Previously, Jeroen worked at Ttopstart BV where he was instrumental in acquiring over EUR 6m in non-dilutive funding for biotech. Prior to this, Jeroen worked in target discovery at Syntaxin Ltd (Oxford, UK). Jeroen received a PhD in immunology from the University of Amsterdam (NL) focusing on the role of innate immune receptors in renal disease. In addition, Jeroen obtained a MSc from the University of Leiden. (NL) with a specialization in science-based business and a BSc in Life Science & Technology from the Technical University of Delft (NL). Jeroen is based in Amsterdam.